Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice

Shichun Lun, Haidan Guo, John Adamson, Justin S. Cisar, Tony D. Davis, Sivagami Sundaram Chavadi, J. David Warren, Luis E N Quadri, Derek S. Tan, William R. Bishai

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Mycobactin biosynthesis in Mycobacterium tuberculosis facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5=-O-(N-salicylsulfamoyl)adenosine] inhibitsM. tuberculosis growth in vitro under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl- AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibitedM. tuberculosis growth in the mouse lung, providing the first in vivo proof of concept for this novel antibacterial strategy.

Original languageEnglish (US)
Pages (from-to)5138-5140
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number10
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Pharmacokinetics
Tuberculosis
Iron
Growth
Intraperitoneal Injections
Mycobacterium tuberculosis
Adenosine
Oral Administration
Virulence
Lung
mycobactins
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Lun, S., Guo, H., Adamson, J., Cisar, J. S., Davis, T. D., Chavadi, S. S., ... Bishai, W. R. (2013). Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice. Antimicrobial Agents and Chemotherapy, 57(10), 5138-5140. https://doi.org/10.1128/AAC.00918-13

Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice. / Lun, Shichun; Guo, Haidan; Adamson, John; Cisar, Justin S.; Davis, Tony D.; Chavadi, Sivagami Sundaram; Warren, J. David; Quadri, Luis E N; Tan, Derek S.; Bishai, William R.

In: Antimicrobial Agents and Chemotherapy, Vol. 57, No. 10, 10.2013, p. 5138-5140.

Research output: Contribution to journalArticle

Lun, S, Guo, H, Adamson, J, Cisar, JS, Davis, TD, Chavadi, SS, Warren, JD, Quadri, LEN, Tan, DS & Bishai, WR 2013, 'Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice', Antimicrobial Agents and Chemotherapy, vol. 57, no. 10, pp. 5138-5140. https://doi.org/10.1128/AAC.00918-13
Lun, Shichun ; Guo, Haidan ; Adamson, John ; Cisar, Justin S. ; Davis, Tony D. ; Chavadi, Sivagami Sundaram ; Warren, J. David ; Quadri, Luis E N ; Tan, Derek S. ; Bishai, William R. / Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice. In: Antimicrobial Agents and Chemotherapy. 2013 ; Vol. 57, No. 10. pp. 5138-5140.
@article{aef2dd541c8c4397bf113d0c00ef509e,
title = "Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice",
abstract = "Mycobactin biosynthesis in Mycobacterium tuberculosis facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5=-O-(N-salicylsulfamoyl)adenosine] inhibitsM. tuberculosis growth in vitro under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl- AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibitedM. tuberculosis growth in the mouse lung, providing the first in vivo proof of concept for this novel antibacterial strategy.",
author = "Shichun Lun and Haidan Guo and John Adamson and Cisar, {Justin S.} and Davis, {Tony D.} and Chavadi, {Sivagami Sundaram} and Warren, {J. David} and Quadri, {Luis E N} and Tan, {Derek S.} and Bishai, {William R.}",
year = "2013",
month = "10",
doi = "10.1128/AAC.00918-13",
language = "English (US)",
volume = "57",
pages = "5138--5140",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice

AU - Lun, Shichun

AU - Guo, Haidan

AU - Adamson, John

AU - Cisar, Justin S.

AU - Davis, Tony D.

AU - Chavadi, Sivagami Sundaram

AU - Warren, J. David

AU - Quadri, Luis E N

AU - Tan, Derek S.

AU - Bishai, William R.

PY - 2013/10

Y1 - 2013/10

N2 - Mycobactin biosynthesis in Mycobacterium tuberculosis facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5=-O-(N-salicylsulfamoyl)adenosine] inhibitsM. tuberculosis growth in vitro under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl- AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibitedM. tuberculosis growth in the mouse lung, providing the first in vivo proof of concept for this novel antibacterial strategy.

AB - Mycobactin biosynthesis in Mycobacterium tuberculosis facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5=-O-(N-salicylsulfamoyl)adenosine] inhibitsM. tuberculosis growth in vitro under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl- AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibitedM. tuberculosis growth in the mouse lung, providing the first in vivo proof of concept for this novel antibacterial strategy.

UR - http://www.scopus.com/inward/record.url?scp=84884225510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884225510&partnerID=8YFLogxK

U2 - 10.1128/AAC.00918-13

DO - 10.1128/AAC.00918-13

M3 - Article

C2 - 23856770

AN - SCOPUS:84884225510

VL - 57

SP - 5138

EP - 5140

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -